Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Diagnostic and Prognostic Value of CMR T1-Mapping in Patients With Heart Failure and Preserved Ejection Fraction.

Rommel KP, Lücke C, Lurz P.

Rev Esp Cardiol (Engl Ed). 2017 Oct;70(10):848-855. doi: 10.1016/j.rec.2017.02.018. Epub 2017 Mar 15. Review. English, Spanish.

PMID:
28314659
2.

Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From a Prospective Cardiac Magnetic Resonance Imaging Study.

Duca F, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Schwaiger ML, Marzluf BA, Bonderman D, Mascherbauer J.

Circ Cardiovasc Imaging. 2016 Dec;9(12). pii: e005277.

PMID:
27974408
3.

Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction.

Rommel KP, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K, Besler C, Sandri M, Lücke C, Gutberlet M, Linke A, Schuler G, Lurz P.

J Am Coll Cardiol. 2016 Apr 19;67(15):1815-1825. doi: 10.1016/j.jacc.2016.02.018.

4.

CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF.

Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, Tseng WY.

JACC Cardiovasc Imaging. 2014 Oct;7(10):991-7. doi: 10.1016/j.jcmg.2014.04.022. Epub 2014 Sep 17.

Supplemental Content

Loading ...
Support Center